-+ 0.00%
-+ 0.00%
-+ 0.00%

NEKTAR THERAPEUTICS - REZOLVE-AD STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS FOR REZPEGALDESLEUKIN 24 ΜG/KG Q2W

路透·08/25/2026 12:30:14

登录查看新闻详情